Clinical Trial Update: A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating A-botulinic Toxin for symptomatic benign prostatic hyperplasia, sponsored by University Hospital, Bordeaux, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• A-botulinic Toxin (botulinum toxin type A)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Prostatic Hyperplasia | Phase 3 | Status: COMPLETED